HC Wainwright Reiterates Buy Rating for GeoVax Labs (NASDAQ:GOVX)

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 220.00% from the company’s current price.

GOVX has been the subject of a number of other reports. EF Hutton Acquisition Co. I upgraded shares of GeoVax Labs to a “strong-buy” rating in a report on Tuesday, July 23rd. Roth Capital raised shares of GeoVax Labs to a “strong-buy” rating in a report on Tuesday, July 16th. Finally, Roth Mkm assumed coverage on shares of GeoVax Labs in a research note on Tuesday, July 16th. They issued a “buy” rating and a $20.00 price objective on the stock.

GeoVax Labs Stock Up 15.2 %

GOVX opened at $2.50 on Monday. The business’s 50 day moving average is $2.33 and its 200-day moving average is $2.14. GeoVax Labs has a twelve month low of $1.09 and a twelve month high of $9.75.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($1.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.57) by $0.58. The business had revenue of $0.30 million during the quarter. During the same quarter last year, the business posted ($3.30) EPS. As a group, equities research analysts forecast that GeoVax Labs will post -7.41 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in GeoVax Labs stock. Armistice Capital LLC bought a new stake in GeoVax Labs, Inc. (NASDAQ:GOVX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned approximately 91.38% of GeoVax Labs at the end of the most recent quarter. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.